RACE ONCOLOGY LTD

2.59%

$1.59

Market Cap $275.3M

Healthcare Biotechnology

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a... Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.More

Corporate Spotlight

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
View the full Corporate Spotlight

RAC Accelerates Game-Changing Cancer Drug

Latest Threads

Tag

Subject

RAC

Ann: Application for quotation of securities - RAC

22:20

1.7K

22:20

Last post asx11

1.7K

RAC

CPACS: Research, Results, Market Comparisons, and Valuations

4 5 6

17:56

348

131K

17:56

Last post Mason14

348

131K

RAC Biotech

RAC - Charts & Price Action

450 451 452

17:54

27K

10M

17:54

Last post FireflyOne

27K

10M

RAC

RAC- Tax discussions

2 3 4

11:01

203

57K

11:01

Last post Rhino1963

203

57K

RAC

RAC media coverage

46 47 48

09:13

2.8K

1.0M

09:13

Last post johndprent

2.8K

1.0M

RAC

General Comments / Chat

235 236 237

10/09/25

14K

5.3M

10/09/25

Last post PlayMoney76

14K

5.3M

RAC

Biotech Valuation (discussions)

08/09/25

3.7K

08/09/25

Last post scolloymore

3.7K

RAC

Piggyback Options (RACOPT43)

06/09/25

5.6K

06/09/25

Last post nextdl

5.6K

RAC

Ann: Appendix 4E & Annual Report

04/09/25

10K

04/09/25

Last post Boffin99

10K

RAC

Ann: Termination of City of Hope Global IP License

2 3

04/09/25

177

63K

04/09/25

Last post ttppxx

177

63K

RAC

Ann: First Hong Kong Site Activated for RC220 Trial

03/09/25

7.9K

03/09/25

Last post Hunterr

7.9K

RAC

Ann: Application for quotation of securities - RAC

02/09/25

2.7K

02/09/25

Last post depps89

2.7K

RAC

Ann: First Patient Safely Combine Dosed in Phase 1 RC220 Trial

3 4 5

02/09/25

269

80K

02/09/25

Last post johndprent

269

80K

RAC

Ann: Race Oncology Upcoming 2025 Investor Events

2 3

01/09/25

175

44K

01/09/25

Last post Hunterr

175

44K

RAC

Industry news

52 53 54

31/08/25

3.2K

1.1M

31/08/25

Last post couldwellb

3.2K

1.1M

RAC

Ann: Quarterly Activity Report and Appendix 4C

28/08/25

112

35K

28/08/25

Last post asx11

112

35K

See All Discussions

Corporate Spotlight

ABOUT US

Timeline

Application for quotation of securities - RAC
11 Sep 14:35	Share

Application for quotation of securities - RAC
02 Sep 13:55	Share

First Hong Kong Site Activated for RC220 Trial
02 Sep 09:21	Share

Appendix 4G
26 Aug 16:48	Share

Corporate Governance Statement
26 Aug 16:47	Share

Appendix 4E & Annual Report
26 Aug 16:45	Share

Phase 2 Bisantrene AML Trial Results Published
04 Aug 13:57	Share

Notification regarding unquoted securities - RAC
24 Jul 16:34	Share

June 2025 Quarterly Activity Report and Appendix 4C
23 Jul 08:28	Share

Race Oncology Upcoming 2025 Investor Events
15 Jul 13:29	Share

RC220 Human Ethics Approvals Received in Hong Kong
10 Jul 09:07	Share

Application for quotation of securities - RAC
26 Jun 13:49	Share

Application for quotation of securities - RAC
19 Jun 14:35	Share

First Patient Safely Combine Dosed in Phase 1 RC220 Trial
19 Jun 08:56	Share

Termination of City of Hope Global IP License
17 Jun 08:57	Share

Application for quotation of securities - RAC
06 Jun 11:54	Share

Notification of cessation of securities - RAC
03 Jun 10:27	Share

Race Gold Coast Brisbane Investor Events
02 Jun 12:14	Share

Application for quotation of securities - RAC
29 May 16:11	Share

Application for quotation of securities - RAC
22 May 11:14	Share

Application for quotation of securities - RAC
07 May 11:09	Share

Notification of cessation of securities - RAC
06 May 15:51	Share

Race Announces Key Senior Clinical Team Appointments
05 May 08:57	Share

First Patient Dosed Safely in RC220 Phase 1 Trial
01 May 08:57	Share

March 2025 Quarterly Activity Report and Appendix 4C
23 Apr 08:41	Share

Enrolment Opened at Second Site for RC220 Phase 1 Trial
22 Apr 08:56	Share

RC220 Phase 1 Trial Opens for Patient Enrolment
03 Apr 08:57	Share

Ethics approval for RC220 Trial at Gosford Wyong Hospitals
31 Mar 17:41	Share

Race Initiates First AU Site for Phase 1 Solid Tumour Trial
27 Mar 15:53	Share

Race Investor Presentation
17 Mar 16:53	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.59		Change 0.040(2.59%)		Mkt cap ! $275.3M

Open	High	Low	Value	Volume
$1.56	$1.61	$1.49	$111.5K	72.94K

Buyers (Bids)

No.	Vol.	Price($)
1	1200	$1.52

Sellers (Offers)

Price($)	Vol.	No.
$1.61	12000	1

View Market Depth

No.	Vol.	Price($)
1	2000	1.510
2	10993	1.505
6	14968	1.500
2	11500	1.480
1	2000	1.450

Price($)	Vol.	No.
1.610	12000	1
1.640	9394	1
1.650	1646	2
1.675	5800	1
1.680	29000	1

Last trade - 16.10pm 11/09/2025 (20 minute delay)


Last $1.56		Change 0.040 ( 0.74 %)
Open	High	Low	Volume
$1.64	$1.64	$1.49	18638
Last updated 15.46pm 11/09/2025 ?

RAC (ASX) Chart

RACE ONCOLOGY LTD

Corporate Spotlight

Latest Threads

Two '4D' stocks to watch, but only one winner

Corporate Spotlight

Timeline

Featured News

Latest Videos

Race Oncology accelerates gamechanging cancer drug

02 Jul 2025 09:48 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

14 May 2024 09:56 (AEST)

Race Oncology (ASX:RAC) strikes contracts to start observational breast cancer trial

13 Mar 2023 15:00 (AEDT)

Latest Articles

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News